MIT Creates AI to Optimize Brain Cancer Treatment

MIT Creates AI to Optimize Brain Cancer Treatment

Advances in medical science have resulted in higher cancer survival rates, but the treatments consisting mainly of chemotherapy and radiation are still rough on patients. A team of researchers from MIT has devised an AI platform that can help. The software takes into account important metrics based on the clinical records of other patients before recommending a regiment designed to shrink brain tumors while lessening the side effects on patients.

The MIT team started with a simple reinforced learning (RL) system similar to the one Google’s DeepMind used to create an unbeatable Go-playing AI. The program consists of “agents” that recommend actions which get you closer to the desired outcome. If the recommendation is good, the agent is rewarded with greater weighting. If not, the agent is penalized and has to adjust its recommendations. Over time, the AI becomes highly optimized at solving a specific problem, in this case creating treatments for glioblastoma, an aggressive form of brain cancer.

The researchers trained the model on 50 simulated glioblastoma patients who sought treatment in the past. The AI conducted 20,000 trial-and-error tests to optimize itself for the best outcomes. After that, the team ran 50 new patient profiles through the model to see what the machine would recommend. The AI usually thinks patients can get the same or better outcome with much less chemotherapy and radiation.

Doctors refer to a number of standard treatment regimens for glioblastoma, which has a mean survival time of just five years. The goal is basically to poison the tumor cells faster than non-cancerous cells, but the side effects of going after an aggressive disease like this can be devastating. These traditional treatment schedules don’t take into account differences in tumor size, medical histories, genetic profiles, and biomarkers. The system developed by MIT does that, resulting in lowered dosages and sometimes even skipping doses altogether.

Glioblastoma example.
Glioblastoma example.

For many simulated patients, the AI recommends a quarter or half dosage at various intervals. Sometimes, it projects a tumor can still shrink even if the patient only comes in for treatment less often than the standard 30 days. Some simulations recommend administering drugs only every six months to shrink tumors.

This system has only been tested in simulations so far, but the researchers believe the science is sound. The FDA has been seeking ways to enhance medical treatment with technology, and this could provide a more precise way of modifying patient care than trusting doctors to use their own judgment. Hopefully, it’s better than Watson.

Continue reading

Huawei Sells Honor Brand Amid Tightening Trade Restrictions
Huawei Sells Honor Brand Amid Tightening Trade Restrictions

(Credit: Kevin Frayer/Getty Images)Huawei has been battered by US trade restrictions in the last few years, and it’s taking a toll on the company’s long-term stability. Experts don’t expect a radical change when the new US administration comes to power next year, so Huawei is beginning to take drastic action. It has sold its Honor…

This Is Your Brain On Electrodes: Nissan’s ‘B2V’ Driver-Skill Amplifier
This Is Your Brain On Electrodes: Nissan’s ‘B2V’ Driver-Skill Amplifier

Nissan's B2V technology — brain-to-vehicle — captures and decodes the driver's brain waves. It can give the car up to a half-second advance notice of the driver's intentions.

Bugatti 3D Prints Titanium Brake Calipers For Chiron Supercar
Bugatti 3D Prints Titanium Brake Calipers For Chiron Supercar

Luxury car manufacturer Bugatti isn't printing with just any metal — no, Bugatti wants to make new brake calipers for its current $2.7 million supercar by 3D printing the parts in titanium.

Windows 10 Build 17093: Multi-GPU controls, Fewer Passwords, HDR Calibration
Windows 10 Build 17093: Multi-GPU controls, Fewer Passwords, HDR Calibration

Microsoft's new Windows 10 Build 17093 shows the company still stuffing features into the upcoming Spring Creators Update. There's some good stuff here.